Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for prognostic systems that incorporate clinical, pathologic, and molecular data to predict survival more accurately in this patient group. In a study published in the Journal of Clinical Oncology, researchers sought to develop a prognostic model for patients with MDS receiving a variety of MDS-targeted treatments. First, they enrolled 1,471 patients with comprehensively annotated clinical and molecular data in a training cohort and analyzed data using machine learning techniques. They ...
Myelodysplastic Syndrome
Explore the newest developments in clinical research and treatment for myelodysplastic syndromes (MDS). Cancer Nursing Today has the latest clinical findings and perspectives on personalized risk prediction models for MDS, genetic mutations related to MDS progression, donor lymphocyte infusions, and more. From clinical trials and screening techniques to the latest treatments, learn how MDS care is evolving.
Advertisement
Latest News
For post-transplant disease control in patients with myelodysplastic syndromes (MDS), donor lymphocyte infusion (DLI) has ...
Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine ...
Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival ...
In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity ...
Treatment with enasidenib, a small molecule inhibitor of mutant IDH2, showed promising clinical activity in patients with ...
A study published in Hematology, Transfusion & Cell Therapy found that FLT3, NPM1, IDH1, and IDH2 gene mutations may ...
Advertisement
Conference Highlights
Advertisement
Advertisement
Popular Stories
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...
